Company Performance - Steris reported quarterly earnings of $2.34 per share, exceeding the Zacks Consensus Estimate of $2.32 per share, and up from $2.03 per share a year ago, representing an earnings surprise of +0.86% [1] - The company posted revenues of $1.39 billion for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 2.36%, compared to $1.28 billion in the same quarter last year [2] - Over the last four quarters, Steris has surpassed consensus EPS estimates three times and topped consensus revenue estimates once [2] Future Outlook - The immediate price movement of Steris shares will depend on management's commentary during the earnings call and the company's earnings outlook [3][4] - The current consensus EPS estimate for the upcoming quarter is $2.39 on revenues of $1.41 billion, and for the current fiscal year, it is $10.12 on revenues of $5.83 billion [7] Industry Context - The Medical - Instruments industry, to which Steris belongs, is currently ranked in the bottom 41% of over 250 Zacks industries, indicating potential challenges ahead [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact Steris's stock performance [5][6]

[Executive Summary & Q1 FY26 Performance](index=1&type=section&id=Executive%20Summary%20%26%20Q1%20FY26%20Performance) [Overall Financial Performance (Q1 FY26)](index=1&type=section&id=Overall%20Financial%20Performance%20(Q1%20FY26)) STERIS began fiscal 2026 with strong performance, reporting a 9% revenue increase to $1.4 billion and exceeding adjusted EPS expectations **Total Company First Quarter Results from Continuing Operations:** | Metric | Q1 FY26 (2025) | Q1 FY25 (2024) | YoY Change | | :--- | :--- | :--- | :--- | | Total Revenue | $1.4 billion | $1.3 billion | +9% | | Constant Currency Organic Revenue Growth | 8% | N/A | N/A | | Net Income | $177.4 million | $139.8 million | +26.9% | | Diluted EPS | $1.79 | $1.41 | +26.9% | | Adjusted Net Income | $231.2 million | $201.7 million | +14.6% | | Adjusted Diluted EPS | $2.34 | $2.03 | +15.3% | - CEO Dan Carestio stated, "We are pleased with a strong start to fiscal 2026. Our performance exceeded expectations and margins improved nicely, despite tariff headwinds. Revenue also benefited from favorable foreign currency during the quarter, which we anticipate will continue throughout the fiscal year."[3](index=3&type=chunk) [Segment Performance (Q1 FY26)](index=1&type=section&id=Segment%20Performance%20(Q1%20FY26)) All three segments demonstrated revenue and operating income growth in Q1 FY26, driven by improved volume, price, and productivity [Healthcare Segment](index=1&type=section&id=Healthcare%20Segment) The Healthcare segment's revenue grew 8% to $974.7 million, driven by strong performance across service, capital equipment, and consumables **Healthcare Segment Q1 FY26 Performance:** | Metric | Q1 FY26 (2025) | Q1 FY25 (2024) | YoY Change | | :--- | :--- | :--- | :--- | | Revenue | $974.7 million | $901.2 million | +8% | | Constant Currency Organic Revenue Growth | 8% | N/A | N/A | | Service Revenue Growth | 13% | N/A | N/A | | Capital Equipment Revenue Growth | 6% | N/A | N/A | | Consumable Revenue Growth | 5% | N/A | N/A | | Operating Income | $235.5 million | $216.9 million | +8.6% | - The increase in operating income was primarily due to **improved volume, price, productivity**, and the benefit of prior restructuring efforts, partially offset by tariffs and inflation[4](index=4&type=chunk) [Applied Sterilization Technologies (AST) Segment](index=1&type=section&id=Applied%20Sterilization%20Technologies%20(AST)%20Segment) AST revenue increased 13% to $281.2 million, driven by strong growth in both service and capital equipment revenue **Applied Sterilization Technologies (AST) Segment Q1 FY26 Performance:** | Metric | Q1 FY26 (2025) | Q1 FY25 (2024) | YoY Change | | :--- | :--- | :--- | :--- | | Revenue | $281.2 million | $249.8 million | +13% | | Constant Currency Organic Revenue Growth | 10% | N/A | N/A | | Service Revenue Growth | 12% | N/A | N/A | | Capital Equipment Revenue Growth | 46% | N/A | N/A | | Operating Income | $136.7 million | $117.7 million | +16.1% | - The operating income increase primarily reflects **improved price and volume**, which more than offset increased energy costs and labor inflation[5](index=5&type=chunk) [Life Sciences Segment](index=1&type=section&id=Life%20Sciences%20Segment) Life Sciences revenue grew 5% to $135.2 million, with consumables leading at 8% growth and operating income improving due to better mix and productivity **Life Sciences Segment Q1 FY26 Performance:** | Metric | Q1 FY26 (2025) | Q1 FY25 (2024) | YoY Change | | :--- | :--- | :--- | :--- | | Revenue | $135.2 million | $128.5 million | +5% | | Constant Currency Organic Revenue Growth | 4% | N/A | N/A | | Consumable Revenue Growth | 8% | N/A | N/A | | Service Revenue Growth | 3% | N/A | N/A | | Capital Equipment Revenue Growth | 1% | N/A | N/A | | Operating Income | $58.7 million | $52.6 million | +11.6% | - Operating income increased reflecting **improvement in mix, price, and productivity**[6](index=6&type=chunk) [Cash Flow Performance (Q1 FY26)](index=1&type=section&id=Cash%20Flow%20Performance%20(Q1%20FY26)) STERIS reported a significant increase in cash flow from operations and free cash flow, primarily driven by earnings growth and improved working capital **Cash Flow Performance Q1 FY26:** | Metric | Q1 FY26 (2025) | Q1 FY25 (2024) | YoY Change | | :--- | :--- | :--- | :--- | | Net Cash Provided by Operations | $420.0 million | $303.7 million | +38.3% | | Free Cash Flow | $326.5 million | $195.7 million | +66.8% | - The increase in free cash flow was driven primarily by the **growth in earnings and improved working capital**[7](index=7&type=chunk) [Company Updates & Fiscal 2026 Outlook](index=2&type=section&id=Company%20Updates%20%26%20Fiscal%202026%20Outlook) [Board of Directors Changes](index=2&type=section&id=Board%20of%20Directors%20Changes) Two board members retired and Louis Shapiro, former President and CEO of Hospital for Specialty Surgery, was elected as a new member - Dr. Jaqueline Kosecoff and Dr. Richard Steeves retired from the Board as of July 31, 2025[9](index=9&type=chunk) - **Louis Shapiro**, retired President and CEO of the Hospital for Specialty Surgery (HSS), has been elected to the Board, adding additional perspective from the healthcare industry[9](index=9&type=chunk)[10](index=10&type=chunk) [Updated Fiscal 2026 Outlook](index=2&type=section&id=Updated%20Fiscal%202026%20Outlook) The company raised its as-reported revenue growth outlook due to favorable currency, while maintaining its adjusted EPS and organic growth expectations **Revised FY26 Revenue Outlook (Continuing Operations):** | Metric | Previous Expectation | Updated Expectation | Change | | :--- | :--- | :--- | :--- | | As reported revenue increase | 6-7% | 8-9% | +2% | | Constant currency organic revenue growth | 6-7% | 6-7% | Unchanged | | Foreign Currency Favorability | N/A | ~200 basis points | New | **Revised FY26 Adjusted EPS Outlook (Continuing Operations):** | Metric | Previous Expectation | Updated Expectation | | :--- | :--- | :--- | | Adjusted EPS range | $9.90 - $10.15 | $9.90 - $10.15 | - Favorable foreign currency changes will be offset by **increased tariffs** (estimated to reduce pre-tax profit by approximately $45 million) and higher employee healthcare benefit costs, resulting in unchanged adjusted EPS[10](index=10&type=chunk) **Revised FY26 Capital Expenditures & Free Cash Flow:** | Metric | Previous Expectation | Updated Expectation | Change | | :--- | :--- | :--- | :--- | | Capital expenditures | N/A | ~$375 million | N/A | | Free cash flow | ~$770 million | ~$820 million | +$50 million | - The increase in free cash flow is due to **improvements in working capital**[11](index=11&type=chunk) [About STERIS & Investor Information](index=2&type=section&id=About%20STERIS%20%26%20Investor%20Information) [About STERIS](index=2&type=section&id=About%20STERIS) STERIS is a global provider of products and services focused on patient care and infection prevention to create a healthier and safer world - STERIS is a leading global provider of products and services that support patient care with an emphasis on **infection prevention**[14](index=14&type=chunk) - The company's mission is to "HELP OUR CUSTOMERS CREATE A HEALTHIER AND SAFER WORLD by providing innovative healthcare and life science products and services around the globe"[14](index=14&type=chunk) [Conference Call Information](index=2&type=section&id=Conference%20Call%20Information) Management will host a conference call on August 7, 2025, at 9:00 a.m. ET to discuss results, with replay options available - A conference call will be hosted on **August 7, 2025, at 9:00 a.m. ET**[12](index=12&type=chunk) - The conference call can be accessed at www.steris-ir.com or via phone (US: 1-833-535-2199, International: 1-412-902-6776)[12](index=12&type=chunk) - A replay will be available starting 12:00 p.m. ET on August 7, 2025, at www.steris-ir.com or via phone (Access Code: 2889488)[13](index=13&type=chunk) [Financial Statements & Supplemental Data](index=5&type=section&id=Financial%20Statements%20%26%20Supplemental%20Data) [Consolidated Condensed Statements of Operations](index=5&type=section&id=Consolidated%20Condensed%20Statements%20of%20Operations) The statement shows significant year-over-year improvements in gross profit, income from operations, and net income from continuing operations **Consolidated Condensed Statements of Operations (in millions, except per share data):** | Metric | Q1 FY26 (2025) | Q1 FY25 (2024) | YoY Change | | :--- | :--- | :--- | :--- | | Revenues | $1,391.1 | $1,279.5 | +8.7% | | Gross profit | $628.0 | $572.4 | +9.7% | | Income from operations | $246.0 | $185.5 | +32.6% | | Income from continuing operations, net of income tax | $178.0 | $139.9 | +27.2% | | Net income attributable to shareholders | $177.4 | $145.4 | +22.0% | | Diluted EPS - Continuing Operations | $1.79 | $1.41 | +26.9% | | Cash dividends declared per share | $0.57 | $0.52 | +9.6% | [Consolidated Condensed Balance Sheets](index=6&type=section&id=Consolidated%20Condensed%20Balance%20Sheets) Total assets increased, driven by higher cash, fixed assets, and goodwill, while total liabilities saw a slight decrease **Consolidated Condensed Balance Sheets (in millions):** | Metric | June 30, 2025 | March 31, 2025 | Change | | :--- | :--- | :--- | :--- | | Cash and cash equivalents | $279.7 | $171.7 | +$108.0 | | Total current assets | $2,057.8 | $2,000.8 | +$57.0 | | Property, plant, and equipment, net | $2,054.8 | $1,956.5 | +$98.3 | | Goodwill | $4,223.1 | $4,095.7 | +$127.4 | | Total assets | $10,405.0 | $10,146.8 | +$258.2 | | Total current liabilities | $926.6 | $1,022.2 | -$95.6 | | Long-term indebtedness | $1,903.1 | $1,918.7 | -$15.6 | | Total equity | $6,969.9 | $6,615.8 | +$354.1 | | Total liabilities and equity | $10,405.0 | $10,146.8 | +$258.2 | [Consolidated Condensed Statements of Cash Flows](index=8&type=section&id=Consolidated%20Condensed%20Statements%20of%20Cash%20Flows) The company shows a substantial increase in net cash from operating activities and free cash flow compared to the prior year **Consolidated Condensed Statements of Cash Flows (in millions):** | Metric | Q1 FY26 (2025) | Q1 FY25 (2024) | Change | | :--- | :--- | :--- | :--- | | Net cash provided by operating activities | $420.0 | $303.7 | +$116.3 | | Net cash (used in) provided by investing activities | $(108.5) | $687.8 | -$796.3 | | Net cash used in financing activities | $(213.1) | $(998.9) | +$785.8 | | Increase (decrease) in cash and cash equivalents | $108.0 | $(8.7) | +$116.7 | | Free Cash Flow | $326.5 | $195.7 | +$130.8 | - The significant change in investing activities is primarily due to **proceeds from the sale of businesses** in the prior year ($809.6 million in Q1 FY25)[28](index=28&type=chunk) [Segment Financial Data](index=7&type=section&id=Segment%20Financial%20Data) This section provides a detailed breakdown of revenues and operating income, highlighting growth across all three business segments **Segment Data (in millions):** | Segment | Q1 FY26 (2025) Revenues | Q1 FY25 (2024) Revenues | YoY Revenue Change | Q1 FY26 (2025) Op. Income | Q1 FY25 (2024) Op. Income | YoY Op. Income Change | | :--- | :--- | :--- | :--- | :--- | :--- | :--- | | Healthcare | $974.7 | $901.2 | +8.2% | $235.5 | $216.9 | +8.6% | | AST | $281.2 | $249.8 | +12.6% | $136.7 | $117.7 | +16.1% | | Life Sciences | $135.2 | $128.5 | +5.2% | $58.7 | $52.6 | +11.6% | | Corporate Operating Loss | $(114.0) | $(101.8) | -12.0% | N/A | N/A | N/A | | Total revenues | $1,391.1 | $1,279.5 | +8.7% | N/A | N/A | N/A | | Total income from operations before adjustments | $316.9 | $285.4 | +11.0% | N/A | N/A | N/A | [Unaudited Supplemental Financial Data](index=12&type=section&id=Unaudited%20Supplemental%20Financial%20Data) Supplemental data provides a breakdown of revenues by product type and geography, along with backlog and income tax rate details **Total Company Revenues - Continuing Operations (Q1 FY26 vs Q1 FY25):** | Revenue Type (in millions) | FY26 Q1 | FY25 Q1 | YoY Change | | :--- | :--- | :--- | :--- | | Consumables | $435.0 | $414.1 | +5.0% | | Service | $700.6 | $623.2 | +12.4% | | Total Recurring | $1,135.6 | $1,037.3 | +9.5% | | Capital Equipment | $255.5 | $242.2 | +5.5% | | Total Revenues | $1,391.1 | $1,279.5 | +8.7% | **Geographic Revenue Distribution (Q1 FY26):** | Region | Revenue (in millions) | % of Total | | :--- | :--- | :--- | | United States | $1,025.6 | 74% | | International | $342.9 | 24% | | Ireland | $22.5 | 2% | **Backlog (Continuing Operations, as of June 30, 2025):** | Segment | Backlog (in millions) | | :--- | :--- | | Healthcare | $403.5 | | Life Sciences | $111.0 | | Total Backlog | $514.5 | **Income Tax Rates (Continuing Operations, Q1 FY26 vs Q1 FY25):** | Tax Rate Type | FY26 Q1 | FY25 Q1 | | :--- | :--- | :--- | | As reported, U.S. GAAP Income Tax Rate | 23.3% | 20.1% | | Adjusted Income Tax Rate | 23.5% | 21.3% | [Non-GAAP Financial Measures](index=2&type=section&id=Non-GAAP%20Financial%20Measures) [Definition and Purpose of Non-GAAP Measures](index=2&type=section&id=Definition%20and%20Purpose%20of%20Non-GAAP%20Measures) STERIS uses non-GAAP measures to provide greater transparency and a more complete understanding of its core operating results - Non-GAAP financial measures are presented to provide **greater transparency** to supplemental financial information used by management and the Board of Directors[15](index=15&type=chunk)[30](index=30&type=chunk) - Adjusted net income, adjusted EPS, and adjusted income from operations **exclude items** such as amortization of acquired intangible assets, acquisition costs, and other unusual or non-recurring items[17](index=17&type=chunk) - **Free cash flow** is defined as cash flows from operating activities less purchases of property, plant, equipment and intangibles, plus proceeds from sales of those assets[18](index=18&type=chunk)[28](index=28&type=chunk) - **Constant currency organic revenue growth** removes the impact of currency exchange rates, acquisitions, and divestitures to measure underlying revenue trends[19](index=19&type=chunk)[32](index=32&type=chunk) - Non-GAAP measures should not be considered replacements for U.S. GAAP results and may not be comparable to similarly titled measures used by other companies[15](index=15&type=chunk)[20](index=20&type=chunk)[31](index=31&type=chunk) [Reconciliation of Non-GAAP Financial Measures](index=9&type=section&id=Reconciliation%20of%20Non-GAAP%20Financial%20Measures) This section provides detailed reconciliations of GAAP to non-GAAP financial measures for revenue, gross profit, net income, and EPS **Segment Revenues - Constant Currency Organic Growth (Q1 FY26):** | Segment | As reported, U.S. GAAP Growth | Constant Currency Organic Growth | | :--- | :--- | :--- | | Healthcare | 8.2% | 7.6% | | AST | 12.6% | 10.2% | | Life Sciences | 5.2% | 4.2% | | Total | 8.7% | 7.8% | **Reconciliation of GAAP to Adjusted Financials (Q1 FY26 vs Q1 FY25, in millions, except EPS):** | Metric | GAAP (2025) | Adjustments (2025) | Adjusted (2025) | GAAP (2024) | Adjustments (2024) | Adjusted (2024) | | :--- | :--- | :--- | :--- | :--- | :--- | :--- | | Gross Profit | $628.0 | $1.6 | $629.6 | $572.4 | $3.8 | $576.6 | | Income from Operations | $246.0 | $71.0 | $316.9 | $185.5 | $100.0 | $285.4 | | Income from continuing operations, net of income tax | $178.0 | $53.8 | $231.8 | $139.9 | $80.6 | $201.7 | | Net income attributable to shareholders | $177.4 | $53.8 | $231.2 | $145.4 | $67.2 | $212.6 | | Diluted EPS from continuing operations | $1.79 | $0.55 | $2.34 | $1.41 | $0.62 | $2.03 | [FY2026 Outlook Non-GAAP Reconciliation](index=11&type=section&id=FY2026%20Outlook%20Non-GAAP%20Reconciliation) This section provides the reconciliation for the fiscal 2026 outlook for adjusted EPS and free cash flow **FY26 Outlook - Adjusted Net Income from Continuing Operations per Diluted Share:** | Metric | Outlook (Ended March 31, 2026) | | :--- | :--- | | Net income from continuing operations per diluted share | $7.79 - $8.04 | | Amortization of acquired intangible assets | $2.08 | | Restructuring | $0.03 | | Adjusted net income from continuing operations per diluted share | $9.90 - $10.15 | **FY26 Outlook - Free Cash Flow (in millions):** | Metric | Outlook (Ended March 31, 2026) | | :--- | :--- | | Cash flows from operating activities | $1,195.0 | | Purchases of property, plant, equipment, and intangibles, net | $(375.0) | | Free Cash Flow | $820.0 | [Cautionary Statement Regarding Forward-Looking Information](index=3&type=section&id=Cautionary%20Statement%20Regarding%20Forward-Looking%20Information) This section advises that forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from projections - The release contains forward-looking statements, identified by terms such as "may," "will," "expects," "believes," "anticipates," and "outlook"[21](index=21&type=chunk) - Actual results could differ materially due to various factors, including **operating costs, pricing pressure, integration of acquisitions, changes in tax laws or tariffs**, and regulatory actions[22](index=22&type=chunk) - Other potential risks include **international unrest, economic downturns, currency fluctuations, increasing competition**, and labor-related issues[23](index=23&type=chunk) - STERIS does not undertake to update or revise any forward-looking statements unless legally required[23](index=23&type=chunk)

Company Transition - Michael J. Tokich is stepping down as CFO after 17 years, effective August 18, 2025, and will become Senior Financial Advisor [2][3] - Karen L. Burton, currently Chief Accounting Officer, will succeed Tokich as CFO [4][5] Financial Performance - Under Tokich's leadership, STERIS's revenue has quadrupled, and market capitalization has increased from $1 billion to $22 billion [3] Leadership Background - Tokich joined STERIS in 2000 and has held various roles, including Assistant Controller, before becoming CFO in 2008 [3][4] - Burton has been with STERIS since 2004, progressing from Assistant Controller to Chief Accounting Officer in 2017 [4][5] Transition Planning - The transition has been described as well-planned, with both Tokich and Burton having worked closely together for 20 years [4][5] - Burton will join STERIS's senior executive board and oversee all global finance functions and IT [4]

Core Insights - STERIS plc reported a strong financial performance for the first quarter of fiscal 2026, with total revenue from continuing operations increasing by 9% to $1.4 billion compared to $1.3 billion in the same period last year [1][8] - The company experienced an adjusted net income of $231.2 million or $2.34 per diluted share, up from $201.7 million or $2.03 per diluted share in the previous year [2][8] Financial Performance - Total revenue from continuing operations increased by 9% to $1.4 billion, with constant currency organic revenue growth at 8% [1][9] - Net income from continuing operations was $177.4 million or $1.79 per diluted share, compared to $139.8 million or $1.41 per diluted share in the first quarter of fiscal 2025 [2][8] - Free cash flow for the first quarter was $326.5 million, an increase from $195.7 million in the prior year [6][10] Segment Performance - Healthcare revenue grew by 8% to $974.7 million, driven by a 13% increase in service revenue, 6% in capital equipment revenue, and 5% in consumable revenue [3][8] - Applied Sterilization Technologies (AST) revenue increased by 13% to $281.2 million, with a 46% rise in capital equipment revenue [4][8] - Life Sciences revenue rose by 5% to $135.2 million, supported by an 8% increase in consumable revenue [5][8] Outlook - The company updated its fiscal 2026 revenue outlook, now expecting an increase of 8-9% compared to previous expectations of 6-7% [9][10] - Adjusted earnings per diluted share are expected to remain in the range of $9.90 to $10.15, despite increased tariffs and higher employee healthcare costs [9][10] - Free cash flow is now anticipated to be approximately $820 million, up from prior expectations of $770 million [10] Board Changes - STERIS announced changes to its Board, with Dr. Jaqueline Kosecoff and Dr. Richard Steeves retiring, and Louis Shapiro being elected to the Board [7][9]

Core Insights - STERIS plc (STE) is set to announce its first-quarter fiscal 2026 results on August 7, with previous quarter adjusted EPS of $2.74, exceeding Zacks Consensus Estimate by 5.79% [1] - The Zacks Consensus Estimate for revenues is $1.36 billion, reflecting a 6.2% increase year-over-year, while EPS is estimated at $2.32, indicating a 14.3% year-over-year growth [2] Revenue Estimates - Healthcare segment is expected to show robust growth driven by increased procedure volumes in the U.S. and gains in pricing and market share [4] - Healthcare capital equipment order growth is anticipated to remain strong despite shipment issues, with projected revenue growth of 5.1% year-over-year [5] - Applied Sterilization Technologies (AST) segment is expected to see organic revenue growth, with revenues likely increasing by 6.3% year-over-year [6][7] Life Sciences Segment - Life Sciences segment revenues may rise by 5.5% year-over-year, supported by favorable mix, pricing, and divestiture, despite a decline in capital equipment revenue [8][9] Earnings Expectations - STERIS has an Earnings ESP of -3.24%, indicating a lower likelihood of beating earnings estimates this quarter [10] - The company currently holds a Zacks Rank of 3, suggesting a hold position [10]

DUBLIN, IRELAND, July 30, 2025 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that the Company will distribute a quarterly interim dividend of $0.63 per share. This represents a $0.06 increase in the dividend and the Company’s 20th consecutive year of dividend growth. The dividend is payable on September 26, 2025, to shareholders of record at the close of business on September 4, 2025. Additional information about the U.S. tax treatment of dividends, including requir ...

Group 1 - Steris is expected to report a year-over-year increase in earnings, with a consensus estimate of $2.32 per share, reflecting a +14.3% change, and revenues projected at $1.36 billion, up 6.2% from the previous year [3][12] - The earnings report is anticipated to be released on August 6, and the actual results will significantly influence the stock price, depending on whether they meet or exceed expectations [2][12] - The consensus EPS estimate has been revised 0.1% higher in the last 30 days, indicating a slight positive adjustment by analysts [4] Group 2 - The Earnings ESP for Steris is -3.24%, suggesting a bearish outlook from analysts, which complicates the prediction of an earnings beat [12] - Historically, Steris has beaten consensus EPS estimates three out of the last four quarters, with a recent surprise of +5.79% in the last reported quarter [13][14] - The Zacks Rank for Steris is currently 3 (Hold), which, combined with the negative Earnings ESP, makes it challenging to predict a positive earnings surprise [12][19] Group 3 - In the broader industry context, CVRx is expected to report a loss of $0.52 per share, indicating a +20% year-over-year change, with revenues projected at $13.46 million, up 14% [18] - CVRx's consensus EPS estimate has remained unchanged over the last 30 days, but it has an Earnings ESP of -0.65%, reflecting a lower Most Accurate Estimate [19]

Core Viewpoint - STERIS plc will host a conference call to discuss its fiscal 2026 first quarter results on August 7, 2025, with a press release detailing financial results to be issued after the U.S. market closes on August 6, 2025 [1][2]. Company Information - STERIS is a leading global provider of products and services that support patient care, focusing on infection prevention and aiming to create a healthier and safer world through innovative healthcare and life science products and services [3]. Conference Call Details - The conference call will take place at 9:00 a.m. ET on August 7, 2025, and can be accessed live via the company's website or by phone [1]. - A replay of the conference call will be available starting at 12:00 p.m. ET on the same day, with specific access codes provided for both U.S. and international callers [2]. Contact Information - For inquiries, the company contact is Julie Winter, Vice President of Investor Relations and Corporate Communications, reachable via email or phone [4].

Core Viewpoint - Steris (STE) has experienced significant selling pressure, declining 6% over the past four weeks, but is now positioned for a potential trend reversal as it is in oversold territory, with analysts expecting better earnings than previously predicted [1]. Group 1: Technical Indicators - The Relative Strength Index (RSI) is a momentum oscillator that indicates whether a stock is oversold, with readings below 30 typically signaling this condition [2]. - STE's current RSI reading is 27.46, suggesting that the heavy selling pressure may be exhausting itself, indicating a potential trend reversal [5]. Group 2: Fundamental Indicators - There is a strong consensus among sell-side analysts that earnings estimates for STE have increased by 0.1% over the last 30 days, which usually correlates with price appreciation in the near term [7]. - STE holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises, further supporting the potential for a turnaround [8].

Core Insights - STERIS plc's Healthcare segment is benefiting from strong market adoption of its infection prevention products and capital equipment, while the Applied Sterilization Technologies (AST) division is seeing solid growth due to increased service revenues [1][4][5] - The company has shown resilience in its stock performance, with a 6.2% increase over the past year, contrasting with a 12.2% decline in the industry [2] - STERIS has a market capitalization of $22.88 billion and an earnings yield of 4.4%, outperforming the industry's -2.9% [2] Healthcare Segment Performance - The Healthcare segment reported a 5% year-over-year revenue growth for the fourth quarter of fiscal 2025, driven by a 6% increase in consumable revenues and a 13% growth in service revenues [4] - The segment achieved a 6% constant currency organic revenue growth for the fiscal fourth quarter, with order growth exceeding 12% [4][8] - Margins improved due to increased volume, favorable pricing, and positive productivity, which offset labor inflation [4] AST Segment Growth - The AST division experienced a 9% year-over-year growth in the fiscal fourth quarter, supported by a 6% increase in service revenues [5] - The division is gaining traction with ethylene oxide sterilization, particularly among manufacturers of single-use sterile technologies for vaccines and biopharmaceuticals [5] - Constant currency organic revenues in the AST segment were in the high single digits, indicating strong demand from bioprocessing and stable global demand from MedTech customers [5] Financial Health - As of the fiscal fourth quarter of 2025, STERIS reduced its long-term debt by 38.5% to $1.92 billion from $3.12 billion a year earlier [6][9] - The company ended the fiscal third quarter with cash and cash equivalents of $171.7 million, exceeding its short-term debt of $125 million [6] - The total debt-to-capital ratio was 22.5%, down 33.2% year over year, indicating improved solvency [9] Challenges Facing the Company - The global macroeconomic environment has negatively impacted STERIS' financial operations, with rising healthcare costs and procurement challenges affecting production costs [10] - Customer consolidation due to competitive pressures and cost reduction measures has led to pricing pressure and potential customer loss for STERIS [11] Earnings Estimates - The Zacks Consensus Estimate for STERIS' fiscal 2026 earnings has increased by 0.9% to $10.11, with revenues projected at $5.83 billion, suggesting a 6.7% growth from fiscal 2024 [12]